Our Company l News & Events
Ikonisys awarded platform contract by neogenomics laboratories for automated cell-based diagnosis
Leading developer of automated cell-based diagnostic products adds major new customer
New Haven, CT, August 1, 2006
Ikonisys Inc. announced today that it is has been awarded a multi-year, multi-unit contract by NeoGenomics Laboratories to procure and deploy the Ikoniscope®, robotic microscopy platform.
"We're very pleased to broaden our relationship with NeoGenomics," said Dr. Petros Tsipouras, Chairman and CEO of Ikonisys, "and we look forward to working with their team to engage the capabilities of our world-class microscopy platform for their cancer diagnostic needs."
Mr. Robert Gasparini, President and Chief Scientific Officer of NeoGenomics Laboratories stated,The Ikonisys robotic microscope truly represents the next generation of FISH (fluorescence in-situ hybridization) analysis automation by allowing previously unreachable analytical sensitivities. We are excited to be the first cancer diagnostic company to fully integrate the Ikonisys robotic microscopy platform into our service.
Ikonisys has developed the Ikoniscope/IkoniLAN®, a robotic microscopy system for fully automated, high throughput signal detection and analysis. In February 2006 the Company announced that the Food and Drug Administration (FDA) cleared for marketing in the United States its automated cell-locating device, the Ikoniscope, fastFISH® amnio Test System. The Company is developing several products and applications for cancer and prenatal diagnosis/screening based on the utilization of its robotic microscopy system.
Ikonisys, a global leader in the advancement of cell-based diagnostic products has developed a platform of robotic microscopy. Based on its proprietary technology, Ikonisys aims to expand this novel field with products in the genetic disease, oncology, and fertility areas. Additional information about Ikonisys can be found at www.ikonisys.com.
About NeoGenomics Laboratories
NeoGenomics Laboratories is a high-complexity CLIA certified clinical laboratory that offers cancer genetic diagnostic testing services including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry and molecular genetic testing. NeoGenomics is headquartered in Fort Myers, FL with a second operation in Nashville, TN and services the needs of oncologists, pathologists, urologists, hospitals and other reference laboratories not offering genetic testing throughout the United States. For additional information about NeoGenomics, visit www.neogenomics.org.